Quantum-Si (QSI)
Builds benchtop systems, kits, and software for research-use protein sequencing.
Something off on this page? Send us feedback.
Sells Platinum and Platinum Pro instruments, sequencing and library-prep kits, and analysis software for research-use protein analysis. Revenue comes mainly from instruments and consumables, with service/software support, while the business is managed as one reportable segment and is moving toward the Proteus roadmap platform.
Commercializes a research-use next-generation protein sequencing workflow built around Platinum and Platinum Pro instruments, library preparation and barcoding kits, sequencing kits, and Platinum Analysis Software. Product revenue comes from instruments and consumables; service revenue comes from maintenance, software access, and training.
Sales are early-commercialization scale and recently skewed international, with a North American channel partner and a broader distributor network supporting adoption. The company reports one segment, and the CEO reviews consolidated performance for resource allocation.
The main execution task is converting life-science researchers from established proteomics workflows to recurring instrument, consumable, and software use. Proteus remains a roadmap platform, so current-platform demand, upgrade planning, and cash-funded launch readiness shape the business.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 14, 2026 | Industrial Alliance Securities | Target | $1.90 | ||
| Mar 4, 2026 | Canaccord Genuity | Target | $1.50 | $1 | |
| Dec 22, 2025 | Canaccord Genuity | Reiterate | Hold | $2 | $1.50 |
| Oct 27, 2025 | Canaccord Genuity | Reiterate | Hold | $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $111.7M · Total debt $3.3M · Total assets $193.6M · Shareholders' equity $180.2M
- Revenue
- $344.0K
- Operating income
- −$25.6M
- Net income
- −$23.5M
No dividends on record.
| Institutions148 holders · as of Jun 30, 2026 | 24.18% | 52.94M shares | |
| Insiders7 holders · as of Aug 28, 2026 | 13.81% | 30.22M shares | |
| Otherremainder | 62.01% | 135.72M shares |
218.88M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (218.88M in the company's Sep 3, 2026 report, 197.82M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Jonathan M. Rothberg1Insiderdirector, 10 percent owner | 9.98% | 19.94M B · 1.90M A | 13Dfiled Aug 28, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 3.46% | 7.58M A | 13Fas of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 3.27% | 7.17M A | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 2.39% | 5.23M A | 13Fas of Jun 30, 2026 |
Nikko Asset Management Americas, Inc.Institution | 1.78% | 3.89M A | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- Jonathan M. Rothberg's transaction reports restate only vehicles that traded; the 2026 ownership statement (19.94M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 23, 2026 | Jeffrey Alan Hawkins | director, officer: President & CEO | −11,311 | $0.8990 |
| Jun 22, 2026 | Jeffrey Alan Hawkins | director, officer: President & CEO | −11,310 | $0.9574 |
| Jun 23, 2026 | John S. Vieceli | officer: Chief Product Officer | −15,112 | $0.8990 |
| Jun 22, 2026 | John S. Vieceli | officer: Chief Product Officer | −15,111 | $0.9574 |
| Jun 23, 2026 | Jeffry R. Keyes | officer: Chief Financial Officer | −4,117 | $0.8990 |
- Thermo Fisher Scientific
Dominant mass spectrometry and Olink affinity-proteomics rival
- Bruker
High-end timsTOF and proteoform mass-spectrometry competitor
- Danaher
Diversified life-science tools rival through SCIEX and workflow scale
- Illumina
SomaLogic owner expanding NGS-enabled affinity proteomics
- Agilent Technologies
Analytical lab-tools competitor in LC-MS proteomics workflows
- Nautilus Biotechnology
Emerging single-molecule proteomics platform peer
- Seer
Proteograph platform rival for deep unbiased proteomics
- Bio-Rad Laboratories
Protein-analysis tools rival in western blotting and assays
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quantum-Si | $0.7676 | +0.04% | $150.5M | — | — | 93.8 | −41.8% |
| Thermo Fisher Scientific | $609.99 | +0.25% | $226.15B | 32.7 | 23.2 | 4.9 | +10.5% |
| Bruker | $60.00 | +1.61% | $8.98B | — | 26.1 | 2.6 | +5.2% |
| Danaher | $209.00 | −0.43% | $147.59B | 37.3 | 23.6 | 5.9 | +5.5% |
| Illumina | $213.57 | +0.10% | $32.26B | 39.8 | 37.2 | 7.2 | +9.4% |
| Agilent Technologies | $152.51 | +0.76% | $42.76B | 29.8 | 23.0 | 5.8 | +8.1% |
| Nautilus Biotechnology | $0.9618 | +3.81% | $122.4M | — | — | 644.2 | — |
| Seer | $2.00 | +1.01% | $108.9M | — | — | 7.9 | −23.4% |
| Bio-Rad Laboratories | $388.51 | +0.02% | $10.46B | 47.1 | 37.7 | 4.0 | −0.1% |
| Median | 37.3 | 24.8 | 5.8 | +5.5% |